Dynamikos GmbH Institut fuer Studien zur Psychischen Gesundheit
- Address
- lock Available on a paid plan
Nervous System Diseases and Alzheimer’s disease research
The Dynamikos GmbH Institut fuer Studien zur Psychischen Gesundheit in Mannheim is conducting clinical research focused on Nervous System Diseases, with a strong emphasis on Alzheimer’s disease and mild to moderate Alzheimer’s disease. These studies are designed to assess new treatment approaches and better understand how they may support cognition and daily functioning.
- Testing new therapies for Alzheimer’s disease
- Evaluating treatment effectiveness for memory and thinking skills
- Studying options for early Alzheimer’s disease and mild to moderate Alzheimer’s disease
Across the site’s trials, the main goal is to improve care for people living with Alzheimer’s disease by exploring whether investigational treatments can enhance cognition, function, and overall symptom control.
Alzheimer’s disease treatment evaluation
Research at this hospital/clinic site includes studies examining whether novel therapies can improve outcomes in Alzheimer’s disease. The focus is on comparing active treatments with placebo to see how well they may support brain function, especially in the early stages of illness.
- Assessing therapies for early Alzheimer’s disease
- Measuring changes in cognition and functional ability
- Comparing investigational medicines with standard control approaches
These trials aim to generate clearer evidence about which treatment strategies may be most helpful for people affected by this progressive neurological condition.
Psychiatric health and cognitive research
Although the site’s current trial portfolio is centered on Alzheimer’s disease, it reflects the broader mission of the Institut für psychische Gesundheit to advance understanding of brain health and cognitive disorders. The research is geared toward finding better ways to evaluate safety, tolerability, and symptom improvement in affected individuals.
- Investigating safety and tolerability of new treatments
- Exploring effects on cognition and everyday function
- Supporting research on brain-related disease management
By focusing on treatment response and patient outcomes, the site contributes to clinical development in neurological and cognitive health research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Fondazione Santa Lucia1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dynamikos GmbH Institut fuer Studien zur Psychischen Gesundheit
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Mirodenafil Dihydrochloride in Early Alzheimer's Disease: A Phase 3 Double-Blind, Randomized, Placebo-Controlled Trial | Aribio Co. Ltd. | Phase III | Not Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE | 1 | Unknown | 2025-08-25 | 2025-08-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.